Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157862 | 0.87 | MEN1 (0.45) | MEN1KMT2ATP53LTB4R2BCHE | |
| SCHEMBL12464655 | 0.87 | LTB4R2 (0.40) | MEN1KMT2ALTB4R2ALDH1A1NPSR1 | |
| SCHEMBL2158539 | 0.85 | ALDH1A1 (0.41) | LTB4R2ALDH1A1NPSR1CNR1 | |
| SCHEMBL2158682 | 0.84 | LTB4R2 (0.48) | MEN1KMT2ATP53LTB4R2ALDH1A1 | |
| SCHEMBL2157748 | 0.83 | LTB4R2 (0.48) | MEN1KMT2ATP53LTB4R2 | |
| SCHEMBL2157848 | 0.81 | RAB9A (0.48) | MEN1KMT2ATP53LTB4R2ALDH1A1 | |
| SCHEMBL2158076 | 0.79 | LTB4R2 (0.47) | TP53LTB4R2 | |
| SCHEMBL2157674 | 0.79 | PTGDR2 (0.42) | MEN1KMT2ALTB4R2ALDH1A1 | |
| SCHEMBL2157867 | 0.78 | PTGDR2 (0.52) | LTB4R2 | |
| SCHEMBL3812638 | 0.78 | MEN1 (0.40) | MEN1KMT2ATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | MEN1 3052/4885KMT2A 3270/4885TP53 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.